Rudiger Hehlmann

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. ncbi request reprint Chronic myeloid leukemia: a model for oncology
    Rudiger Hehlmann
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Wiesbadener Strasse 7 11, 68305 Mannheim, Germany
    Ann Hematol 84:487-97. 2005
  2. ncbi request reprint Chronic myeloid leukaemia
    Rudiger Hehlmann
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Lancet 370:342-50. 2007
  3. ncbi request reprint Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene
    Christoph Walz
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Genes Chromosomes Cancer 45:950-6. 2006
  4. ncbi request reprint Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up
    Tanja Lahaye
    III Medizinische Klinik Mannheim der Universität Heidelberg, Mannheim, Germany
    Cancer 103:1659-69. 2005
  5. doi request reprint Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib
    Alice Fabarius
    III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Wiesbadener Strasse 7 11, 68305 Mannheim, Germany
    Haematologica 93:1145-54. 2008
  6. doi request reprint Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study
    Georgia Metzgeroth
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Br J Haematol 143:707-15. 2008
  7. pmc Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy
    Benjamin Hanfstein
    III Medizinische Klinik, Universitatsmedizin Mannheim, Universitat Heidelberg, Mannheim, Germany
    Haematologica 96:360-6. 2011
  8. doi request reprint Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib
    Thomas Ernst
    III Medizinische Klinik, Medizinische, Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Haematologica 93:186-92. 2008
  9. doi request reprint Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia
    Thomas Ernst
    III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Clin Chem Lab Med 46:318-22. 2008
  10. doi request reprint Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study
    Kirsten Merx
    III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Theodor Kutzer Ufer 1 3, 68167, Mannheim, Germany
    Ann Hematol 92:907-15. 2013

Detail Information

Publications56

  1. ncbi request reprint Chronic myeloid leukemia: a model for oncology
    Rudiger Hehlmann
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Wiesbadener Strasse 7 11, 68305 Mannheim, Germany
    Ann Hematol 84:487-97. 2005
    ..This review deals with some of the recent developments that have evolved since our last review in this journal in 2000 (Hehlmann R, Hochhaus A, Berger U, Reiter A (2000) Current trends in the management of chronic myelogenous leukemia...
  2. ncbi request reprint Chronic myeloid leukaemia
    Rudiger Hehlmann
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Lancet 370:342-50. 2007
    ..Up to 87% of patients achieve complete cytogenetic remission, therefore we provide guidance for monitoring disease status. Many trials of new drugs and combination therapies that include imatinib are underway...
  3. ncbi request reprint Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene
    Christoph Walz
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Genes Chromosomes Cancer 45:950-6. 2006
    ....
  4. ncbi request reprint Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up
    Tanja Lahaye
    III Medizinische Klinik Mannheim der Universität Heidelberg, Mannheim, Germany
    Cancer 103:1659-69. 2005
    ..The advent of imatinib has considerably changed the treatment of chronic myeloid leukemia (CML). Early studies demonstrated high rates of hematologic and cytogenetic responses in all phases of the disease after limited observation periods...
  5. doi request reprint Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib
    Alice Fabarius
    III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Wiesbadener Strasse 7 11, 68305 Mannheim, Germany
    Haematologica 93:1145-54. 2008
    ..Dasatinib is a multitargeted inhibitor of ABL, the SRC family, and other tyrosine kinases. We sought to evaluate the effects of this drug on cell proliferation, centrosomes, mitotic spindles, and cell cycle progression in vitro and in vivo...
  6. doi request reprint Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study
    Georgia Metzgeroth
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Br J Haematol 143:707-15. 2008
    ..These data confirmed the long-term efficacy of imatinib for PDGFR-rearranged CEL patients, and also showed that a minority of HES cases without known molecular aberrations may benefit from imatinib...
  7. pmc Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy
    Benjamin Hanfstein
    III Medizinische Klinik, Universitatsmedizin Mannheim, Universitat Heidelberg, Mannheim, Germany
    Haematologica 96:360-6. 2011
    ..The expansion of mutant BCR-ABL-positive clones under selective pressure of tyrosine kinase inhibition is referred to as clonal selection; there are few data on the reversibility of this phenomenon...
  8. doi request reprint Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib
    Thomas Ernst
    III Medizinische Klinik, Medizinische, Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Haematologica 93:186-92. 2008
    ..We sought to improve the diagnostic armamentarium by screening and to analyze the dynamics of mutated clones in chronic myeloid leukemia patients who experienced hematologic or cytogenetic relapse...
  9. doi request reprint Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia
    Thomas Ernst
    III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Clin Chem Lab Med 46:318-22. 2008
    ..In CML, blood but not bone marrow samples have been examined using RNA stabilization in previous studies. Therefore, we sought to investigate the applicability of the PAXgene system for bone marrow samples in CML...
  10. doi request reprint Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study
    Kirsten Merx
    III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Theodor Kutzer Ufer 1 3, 68167, Mannheim, Germany
    Ann Hematol 92:907-15. 2013
    ..In six investigated patients, no significant reduction of the JAK2V617F burden was observed despite clinical improvement. The results show that imatinib has moderate cytoreductive effects in PV...
  11. ncbi request reprint Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia
    Andreas Reiter
    III Medizinische Universitätsklinik, Klinikum Mannheim, Fakultät für Klinische Medizin der Universität Heidelberg, Germany
    Genes Chromosomes Cancer 36:175-88. 2003
    ..These findings are consistent with the hypothesis that the t(15;17) occurs by nonhomologous recombination of DNA after processing of the double-strand breaks by a dysfunctional DNA damage-repair mechanism...
  12. doi request reprint Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
    Alice Fabarius
    Medizinische Universitatsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Blood 118:6760-8. 2011
    ..001) than in patients with standard t(9;22). We conclude that major-route ACAs at diagnosis are associated with a negative impact on survival and signify progression to the accelerated phase and blast crisis...
  13. ncbi request reprint Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability
    Alice Fabarius
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Br J Haematol 138:369-73. 2007
    ..Our data suggest that distinct tyrosine kinases likewise targeted by both drugs are essential actuators in maintenance of centrosome and karyotype integrity...
  14. pmc Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group
    Eva Lengfelder
    Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany
    Ann Hematol 92:41-52. 2013
    ..Therefore, new less toxic treatment approaches with broader applicability are needed. Elderly patients might be a particular target group for concepts with arsenic trioxide...
  15. ncbi request reprint Soluble transferrin receptor and zinc protoporphyrin--competitors or efficient partners?
    Georgia Metzgeroth
    III Medizinische Universitätsklinik Mannheim, University of Heidelberg, Wiesbadenerstrasse 7 11, 68305 Mannheim, Germany
    Eur J Haematol 75:309-17. 2005
    ..sTfR also reflects erythropoietic activity, it is increased in enhanced erythropoiesis...
  16. doi request reprint ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
    Thomas Ernst
    III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Wiesbadener Str 7 11, 68305 Mannheim, Germany
    Haematologica 93:1389-93. 2008
    ..Novel point mutations should be confirmed by analyzing the normal ABL alleles to exclude polymorphisms...
  17. ncbi request reprint Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial
    Senta Ulrike Gnad-Vogt
    Onkologisches Zentrum, III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Anticancer Drugs 16:435-40. 2005
    ..Its safety and good tolerability as established in the phase I trial was confirmed...
  18. ncbi request reprint Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure
    Alice Fabarius
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Ruprecht Karls Universität Heidelberg, Mannheim, Germany
    Haematologica 92:834-7. 2007
    ..Seventy-one patients treated with dasatinib after imatinib failure for a median of nine months were evaluated. Novel aberrations within Ph positive and negative clones appeared in six and three patients, respectively...
  19. ncbi request reprint Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene
    Christoph Walz
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Wiesbadener Str 7 11 68305 Mannheim, Germany
    Haematologica 92:163-9. 2007
    ....
  20. ncbi request reprint Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells
    Heiko Konig
    III Medizinische Klinik, Medizinische Fakultat Mannheim, Universitat Heidelberg, Mannheim, Germany
    Haematologica 92:838-41. 2007
    ..These data provide a rationale for the clinical development of optimized ATO-based regimens through incorporation of GSH-modulators in CML treatment...
  21. doi request reprint Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
    Susanne Saussele
    III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Blood 115:1880-5. 2010
    ..We conclude that allo SCT could become the preferred second-line option after imatinib failure for suitable patients with a donor. The study is registered at the National Institutes of Health, http://clinicaltrials.gov: NCT00055874...
  22. pmc DNA microarray-based detection and identification of fungal pathogens in clinical samples from neutropenic patients
    Birgit Spiess
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Theodor Kutzer Ufer 1 3, D 68167, Mannheim, Germany
    J Clin Microbiol 45:3743-53. 2007
    ..The assay detected genomic DNA from 14 fungal pathogens from the clinical samples, pointing to a high significance for improving the diagnosis of IFI...
  23. doi request reprint Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV
    Lida Kalmanti
    III Medizinische Klinik, Universitatsmedizin Mannheim, Pettenkoferstrasse 22, 68169, Mannheim, Germany
    Ann Hematol 93:71-80. 2014
    ..We conclude that AYAs show more aggressive features and poor prognostic indicators possibly indicating differences in disease biology. This, however, does not affect outcome. ..
  24. ncbi request reprint The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia
    Georgia Metzgeroth
    III Medizinische Universitätsklinik, Medizinische Fakultat Mannheim, Universitat Heidelberg, Mannheim, Germany
    Clin Chem Lab Med 45:1313-8. 2007
    ..The soluble transferrin receptor (sTfR) is a parameter of erythropoietic activity and iron deficiency. Increased levels have also been described in hematological malignancies, especially in chronic lymphocytic leukemia (CLL)...
  25. ncbi request reprint Peritoneal haematopoiesis in acute panmyelosis with myelofibrosis
    Georgia Metzgeroth
    III Medizinische Universitätsklinik, Klinikum Mannheim, University of Heidelberg, Germany
    Br J Haematol 130:1. 2005
  26. ncbi request reprint Alveolar rhabdomyosarcoma with bone marrow infiltration mimicking haematological neoplasia
    Ole Maywald
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Br J Haematol 119:583. 2002
  27. ncbi request reprint Systemic mastocytosis simulating osseous metastatic disease
    Georgia Metzgeroth
    III Medizinische Universitätsklinik, Universit of Heidelberg, Mannheim, Germany
    Br J Haematol 136:1. 2007
  28. doi request reprint Treatment of chronic myeloid leukemia when imatinib fails
    Rudiger Hehlmann
    III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Pettenkoferstrasse 22, Mannheim, Germany
    Expert Opin Pharmacother 12:269-83. 2011
    ..Imatinib failure represents a major clinical challenge in the management of chronic myeloid leukemia...
  29. ncbi request reprint Reliable identification of small cell lung cancer in cytological specimens by immunocytology
    Georgia Metzgeroth
    III Medizinische Universitätsklinik, Medizinische Fakultät Manheim, Universitat Heidelberg, Germany
    Onkologie 30:311-5. 2007
    ..A reliable diagnosis of small cell lung cancers (SCLC) is of high clinical relevance. We investigated whether immunocytology substantially improves the diagnostic accuracy of conventional cytology in diagnosing SCLC...
  30. doi request reprint Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study
    Georgia Metzgeroth
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Wiesbadener Str 7 11, 68305 Mannheim, Germany
    Ann Hematol 88:301-10. 2009
    ..No hematologic toxicities were observed. Deferasirox proved to be effective in transfusion-dependent iron overload in MDS by mobilizing iron deposits in liver and at least stabilizing iron stores in bone marrow...
  31. pmc The European LeukemiaNet: achievements and perspectives
    Rudiger Hehlmann
    Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Haematologica 96:156-62. 2011
    ..Its concept has led to funding by the European Commission as a network of excellence. Other sources (European Science Foundation; European LeukemiaNet-Foundation) will take over when the support of the European Commission ends...
  32. ncbi request reprint Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia
    Rudiger Hehlmann
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Wiesbadener Strasse 7 11, 63805 Mannheim, Germany
    Blood 109:4686-92. 2007
    ..032). The general recommendation of HSCT as first-line treatment option in chronic phase CML can no longer be maintained. It should be replaced by a trial with modern drug treatment first...
  33. ncbi request reprint Treatment concepts of acute promyelocytic leukemia
    Eva Lengfelder
    Medizinische Universitatsklinik, Klinikum Mannheim, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Wiesbadener Str 7 11, 68305 Mannheim, Germany
    Crit Rev Oncol Hematol 56:261-74. 2005
    ..Refining the molecular monitoring of MRD by quantitative RT-PCR, better elucidation of the biologic mechanisms, and the identification of prognostic factors might be helpful to make further progress in the treatment of APL...
  34. ncbi request reprint [Drug therapy of chronic myeloid leukemia]
    Andreas Hochhaus
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim
    Med Klin (Munich) 97:7-15. 2002
    ..91% of all CML patients in chronic phase achieve a hematologic remission within 11 months and 55% cytogenetic remission. In blast crisis, 29% achieve hematologic remission which may be durable...
  35. ncbi request reprint Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer
    Ralf Dieter Hofheinz
    Onkologisches Zentrum, III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Theodor Kutzer Ufer, D 68167 Mannheim, Germany
    J Clin Oncol 23:1350-7. 2005
    ..To establish the feasibility and efficacy of capecitabine in combination with weekly irinotecan (CAPIRI) with concurrent pelvic radiotherapy (RT) in patients with locally advanced rectal cancer...
  36. pmc Variable transcriptional activity of endogenous retroviruses in human breast cancer
    Oliver Frank
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Wiesbadener Strasse 7 11, D 68305 Mannheim, Germany
    J Virol 82:1808-18. 2008
    ..No evidence for MMTV or human MMTV-like virus transcripts was found, indicating that transcriptionally active, MMTV analogous, exogenous viruses were not present in the breast cancer samples analyzed...
  37. ncbi request reprint The soluble transferrin receptor in dysplastic erythropoiesis in myelodysplastic syndrome
    Georgia Metzgeroth
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Eur J Haematol 79:8-16. 2007
    ..This study investigated sTfR concentrations in ineffective, dysplastic erythropoiesis in myelodysplastic syndrome (MDS)...
  38. ncbi request reprint Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study
    Ralf Dieter Hofheinz
    Onkologisches Zentrum, III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Anticancer Drugs 16:39-45. 2005
    ..Efficacy and toxicity data are comparable to 5-FU/irinotecan combinations, although the likelihood of severe diarrhea appears to be higher with capecitabine/irinotecan...
  39. ncbi request reprint Leukocytoclastic vasculitis and acute renal failure after influenza vaccination in an elderly patient with myelodysplastic syndrome
    Silke Ulm
    III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Germany
    Onkologie 29:470-2. 2006
    ..Side effects which are seen in 1-10% of the vaccinated individuals are usually mild and consist of local reactions and constitutional symptoms. Since 1974, about 30 cases of vasculitis following influenza vaccination have been reported...
  40. ncbi request reprint Diagnostic yield of bronchoscopy with bronchoalveolar lavage in febrile patients with hematologic malignancies and pulmonary infiltrates
    Margit Hummel
    3 Medizinische Klinik, Universitatsklinikum Mannheim, University of Heidelberg, Mannheim, Germany
    Ann Hematol 87:291-7. 2008
    ....
  41. ncbi request reprint Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study
    Ralf Hofheinz
    Onkologisches Zentrum, III Medizinische Klinik
    Anticancer Drugs 13:999-1004. 2002
    ..The toxicity profile in our series compared to 3-weekly CPT-11 seems favorable...
  42. ncbi request reprint Current molecular diagnostic approaches to systemic infections with aspergillus species in patients with hematological malignancies
    Dieter Buchheidt
    3 Medizinische Klinik, Universitatsklinikum Mannheim, Ruprecht Karls Universitat Heidelberg, Germany
    Leuk Lymphoma 45:463-8. 2004
    ..The clinical value, advantages and remaining problems of recently developed molecular approaches to detect the emerging fungal pathogen are reviewed...
  43. ncbi request reprint Detection of Aspergillus DNA by a nested PCR assay is superior to blood culture in an experimental murine model of invasive aspergillosis
    Margit Hummel
    III Medizinische Klinik, Universitäts klinikum Mannheim, Universitat Heidelberg, D 68305 Mannheim, Germany
    J Med Microbiol 53:803-6. 2004
    ..6 and 87.5 % depending on the fungal burden. In conclusion, the nested PCR assay is superior to cultural methods in detecting Aspergillus spp. in murine blood samples...
  44. ncbi request reprint Management of infections in critically ill neutropenic cancer patients
    Dieter Buchheidt
    Intensive Care Unit, III Medizinische Klinik, Universitatsklinikum Mannheim, University of Heidelberg, Germany
    J Crit Care 19:165-73. 2004
    ..A multidisciplinary practical approach to evaluation and treatment is needed to optimize treatment results and to meet the various diagnostic and therapeutic challenges in this subset of patients on an intensive care unit...
  45. pmc Human endogenous retrovirus expression profiles in samples from brains of patients with schizophrenia and bipolar disorders
    Oliver Frank
    Medical Clinic III, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Germany
    J Virol 79:10890-901. 2005
    ..Our data suggest that HERV transcription in brains is weakly correlated with schizophrenia and related diseases but may be influenced by the individual genetic background, brain-infiltrating immune cells, or medical treatment...
  46. ncbi request reprint Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients
    Dieter Buchheidt
    III Medizinische Universitätsklinik, Klinikum Mannheim, Mannheim, Germany
    Br J Haematol 116:803-11. 2002
    ..4%, the positive predictive value 83.8%, the negative predictive value 98.1%. Our data support the considerable clinical value of this PCR assay for confirming and improving diagnosis of pulmonary aspergillosis in high-risk patients...
  47. ncbi request reprint Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological s
    Dieter Buchheidt
    III Medizinische Klinik, Universitaetsklinikum Mannheim, Universitaet Heidelberg, Wiesbadenerstrasse 7 11, D 68305 Mannheim, Germany
    Br J Haematol 125:196-202. 2004
    ..In patients at high risk for IA, positive results for Aspergillus by PCR of blood samples are highly suggestive for IA and contribute to the diagnosis...
  48. ncbi request reprint IgA nephropathy and hodgkin's disease: a rare coincidence. Case report and literature review
    Jörg Bergmann
    Third Department of Internal Medicine Hematology Oncology, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany
    Am J Kidney Dis 45:e16-9. 2005
    ..Treatment with the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen resulted in complete hematologic and renal remission for more than 1 year after diagnosis...
  49. ncbi request reprint An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR
    Martin C Muller
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Haematologica 92:970-3. 2007
    ..5 mL samples tested positive. For higher dilutions, a PB volume of 5 or 10 ml was required to improve sensitivity. The study showed the feasibility of RQ-PCR standardization independent of the PCR machine used...
  50. ncbi request reprint [Clinical research within the German competence net "acute and chronic leukemias"]
    Susanne Saussele
    Netzwerkzentrale des Kompetenznetzes Akute und chronische Leukämien, III Medizinische Universitätsklinik, Klinikum Mannheim der Universität Heidelberg, Mannheim
    Med Klin (Munich) 101:414-20. 2006
    ..Progress is hampered, however, by fragmentation of leukemia trial groups, diagnostic approaches and treatment research activities...
  51. ncbi request reprint Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase
    Margit Hummel
    III Medizinische Klinik, Klinikum Mannheim, University of Heidelberg, Mannheim, Germany
    Eur J Haematol 75:518-21. 2005
    ..In several studies, rasburicase, given at a dose of 0.15-0.2 mg/kg for up to 7 d, proved to be highly effective in lowering urate levels...
  52. ncbi request reprint Assessment of retroviral activity using a universal retrovirus chip
    Wolfgang Seifarth
    Medical Clinic III, Faculty of Clinical Medicine Mannheim, University of Heidelberg, D 68305, Mannheim, Germany
    J Virol Methods 112:79-91. 2003
    ..Furthermore, it could improve significantly the safety of gene therapy, tissue engineering, xenotransplantation and production of therapeutic polypeptides in cell culture...
  53. ncbi request reprint Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient
    Ralf Dieter Hofheinz
    III Medical Clinic, University Hospital Mannheim, University of Heidelberg, Wiesbadener Strasse 7 11, 68167 Mannheim, Germany
    Cancer Chemother Pharmacol 53:276-7. 2004
    ..We report here a third patient with an immune-haematological finding favouring a bispecific mechanism (immune-complex and penicillin type) of oxaliplatin-induced haemolysis...
  54. ncbi request reprint Zinc protoporphyrin, a useful parameter to address hyperferritinemia
    Georgia Metzgeroth
    III Medizinische Universitätsklinik Mannheim, Medizinische Fakultat Mannheim, Universitat Heidelberg, Mannheim, Germany
    Ann Hematol 86:363-8. 2007
    ..Showing significantly lower values in HE, ZPP seems to be a useful parameter in distinguishing HE from other hyperferritinemic disorders as those conditions are generally accompanied by an increased ZPP...
  55. ncbi request reprint The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
    Andreas Reiter
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Cancer Res 65:2662-7. 2005
    ..We conclude that human autoantigen pericentriolar material (PCM1)-JAK2 is a novel, recurrent fusion gene in hematologic malignancies. Patients with PCM1-JAK2 disease are attractive candidates for targeted signal transduction therapy...
  56. pmc Comprehensive analysis of human endogenous retrovirus transcriptional activity in human tissues with a retrovirus-specific microarray
    Wolfgang Seifarth
    Medical Clinic III, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Mannheim, Germany
    J Virol 79:341-52. 2005
    ..Distinct activity patterns may reflect the characteristics of the regulatory machinery in these cells, e.g., cell type-dependent occurrence of transcriptional regulatory factors...